FDA Accepts NDA220482 from HAISCO Pharmaceutical for Review
The FDA has accepted the New Drug Application NDA220482 from HAISCO Pharmaceutical for review under standard priority.
Asset / Drug
Drug and asset intelligence for NDA220482 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.